Pharma

Pharmalot By Ed Silverman

‘Late is better than never’: Biden plan to boost U.S. production of Covid vaccines gets mixed reviews

Pharmalot By Ed Silverman

‘Can’t get much worse’: What a European rejection of an Alzheimer’s drug would mean for Biogen

Pharmalot By Ed Silverman

FDA is urged to disqualify a hospital review board and two doctors over clinical trial missteps

Pharmalot By Ed Silverman

Pharmalittle: European regulators unlikely to approve Biogen Alzheimer’s drug; U.S. to invest billions to expand Covid vaccine production

Pharmalot By Ed Silverman

‘Where’s my prescription?’: California wants to revoke an OptumRx pharmacy license for prescribing lapses

Pharmalot By Ed Silverman

Pfizer to file for emergency authorization Tuesday for its Covid-19 pill

Pharmalot By Ed Silverman

Pharmalittle: Biogen R&D chief retiring amid controversy over Alzheimer’s drug; Pfizer strikes deal for generic versions of its Covid pill

Pharmalot By Ed Silverman

The prices of 7 drugs were hiked without proof of new benefits, costing the U.S. $1.6 billion in 2020

Pharmalot By Ed Silverman

Pfizer strikes a deal with the Medicines Patent Pool for generic versions of its Covid-19 pill in poor countries

Pharmalot By Ed Silverman

Conflicts of interest are common among editors and authors of psychopharmacology textbooks

Pharmalot By Ed Silverman

Biogen’s pricey Alzheimer’s drug will fuel record premium hikes for Medicare Part B

Pharmalot By Ed Silverman

Pharmalittle: Califf has lots of unfinished FDA business; FDA’s warnings prompt trial sponsors to report results

Pharmalot By Ed Silverman

When FDA rattles its sabre, drug makers and universities start reporting overdue trial results

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalittle: J&J to split into two companies; AstraZeneca will price its Covid-19 vaccine to make it profitable

Pharmalot By Ed Silverman

‘A work in progress’: BioNTech’s CEO wants to widen Covid-19 vaccine access on his own terms

Pharmalot By Ed Silverman

Pharmalittle: NIH to fight Moderna in court over Covid-19 vaccine patents; ‘puzzling’ results in an Alzheimer’s study

Biotech By Adam Feuerstein

‘Quite puzzling’ results in Alzheimer’s study cloud future of tau-targeting antibody treatment

Pharmalot By Ed Silverman

Pharmalittle: Moderna and NIH clash over Covid-19 vaccine patent; Biogen probes Alzheimer’s patient death

Pharmalot By Ed Silverman

Company that sold overdose antidote to pay $12.7 million to settle charges of fraudulent scheme

Pharmalot By Ed Silverman

Obesity journal editor’s extensive company ties raise concerns about conflicts of interest in publishing

Pharmalot By Ed Silverman

Oklahoma court overturns $465 million opioid verdict against Johnson & Johnson

Pharmalot By Ed Silverman

Pharmalittle: Pelosi was the real holdout in drug-pricing talks; U.S. to pay $1 billion for more Merck Covid pills

Pharmalot By Ed Silverman

A controversial drug for premature births, which FDA wants withdrawn, is tied to elevated cancer risk

Pharmalot By Ed Silverman

Hospitals charge insurers and cash-paying patients much more than what Medicare pays for some infused drugs

Pharmalot By Ed Silverman

Pharmalittle: Court rulings on 340B drug discounts conflict; Swiss socialists want government to buy Sandoz

Pharmalot By Ed Silverman

New court rulings add to the confusing and controversial dispute over a U.S. drug discount program

Pharmalot By Ed Silverman

Clinical trial sites face challenges in diversifying personnel and participants, study finds

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings